Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.hrthm.2019.08.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cardioneuroablation can be an effective strategy to treat glossopharyngeal neuralgia-related sinus bradycardia and pauses.
J Cardiovasc Electrophysiol
October 2024
Department of CV Medicine, Heart, Vascular & Thoracic Institute, Cleveland Clinic, Cleveland, USA.
Introduction: Cardioneuroablation (CNA) has proven effectiveness in addressing hypervagotonia symptoms, such as neurocardiogenic syncope.
Methods And Results: In this case, we present the first-time application of CNA in a case of vago-glossopharyngeal neuralgia (VGPN). A 59-year-old female with near-syncope, sinus bradycardia, and sinus pauses triggered by recurrent right-sided neck pain was diagnosed with VGPN.
Long-term outcomes of cardioneuroablation with and without extra-cardiac vagal stimulation confirmation in severe cardioinhibitory neurocardiogenic syncope.
J Cardiovasc Electrophysiol
April 2024
Sao Paulo Heart Hospital, Sao Paulo, Brazil.
Background: Cardioneuroablation (CNA) is a novel therapeutic approach for functional bradyarrhythmias, specifically neurocardiogenic syncope or atrial fibrillation, achieved through endocardial radiofrequency catheter ablation of vagal innervation, obviating the need for pacemaker implantation. Originating in the nineties, the first series of CNA procedures was published in 2005. Extra-cardiac vagal stimulation (ECVS) is employed as a direct method for stepwise denervation control during CNA.
View Article and Find Full Text PDFCardioneuroablation for severe neurocardiogenic syncope.
Rev Port Cardiol
October 2023
Centro Hospitalar Vila Nova de Gaia/Espinho, Cardiology Department, V. N. Gaia, Portugal.
Introduction And Objectives: Cardioneuroablation (CNA), a technique based on radiofrequency ablation of cardiac vagal ganglia, was developed to treat recurrent vasovagal syncope (VVS) with a predominant cardioinhibitory component, as an alternative to pacemaker implantation. The aim of our study was to evaluate the safety and success rate of CNA guided by extracardiac vagal stimulation in patients with highly symptomatic cardioinhibitory VVS.
Methods: Prospective study of patients who underwent anatomically guided CNA at two cardiology centers.
Ganglionated plexi ablation in the right atrium for the treatment of cardioinhibitory syncope.
Eur Heart J Suppl
May 2023
Department of Cardiology, Policlinico Casilino, Via Casilina 1049, 00100 Rome, Italy.
Neurocardiogenic syncope, also called vasovagal syncope, represents one of the clinical manifestations of neurally mediated syncopal syndrome. Generally, the prognosis of the cardioinhibitory form of neurocardiogenic syncope is good, but quality of life is seriously compromised in patients who experience severe forms. Drug therapy has not achieved good clinical results and very heterogeneous data come from studies regarding permanent cardiac pacing.
View Article and Find Full Text PDFImproved health-related quality of life after cardioneuroablation in patients with vasovagal syncope.
J Interv Card Electrophysiol
November 2022
Department of Cardiology, Yeditepe University Hospital, Istanbul, Turkey.
Background: As the most common cause of syncope, vasovagal syncope (VVS) is mediated by parasympathetic overactivity and/or sympathetic withdrawal. Although catheter ablation of ganglionated plexi or cardioneuroablation has been used to treat VVS, its role in quality of life (QoL) has not been formally evaluated. The aim of this study was to demonstrate if this novel treatment results in improvement QoL of patients with VVS.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!